您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Docetaxel-d9
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Docetaxel-d9
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Docetaxel-d9图片
CAS NO:940867-25-4
包装与价格:
包装价格(元)
500 μg电议
1mg电议

产品介绍
Docetaxel-d9 (RP-56976-d9) 是氘标记的 Docetaxel。 Docetaxel (RP-56976) 是一种微管解聚抑制剂,IC50 为 0.2 μM。多西他赛减弱 bcl-2 和 bcl-xL 基因表达的影响。 Docetaxel 在 G2/M 停止细胞周期并导致细胞凋亡。多西他赛具有抗癌活性。
Cas No.940867-25-4
别名多烯紫杉醇D9,RP-56976-d9
Canonical SMILESCC(C1=C(C)[C@@H](OC([C@H](O)[C@@H](NC(OC(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)C2=CC=CC=C2)=O)C3)(C)[C@]3(O)[C@@H](OC(C4=CC=CC=C4)=O)[C@@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]6O)([H])[C@]6(C)C([C@@H]1O)=O
分子式C43H44D9NO14
分子量816.9
溶解度Chloroform: Slightly Soluble,Methanol: Slightly Soluble
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Docetaxel-d9is intended for use as an internal standard for the quantification of docetaxel by GC- or LC-MS. Docetaxel is a semisynthetic analog of paclitaxel that inhibits microtubule disassembly (IC50= 0.2 μM) and inhibits cell replication (IC50= 0.13 μM).1It has proven more effective than taxol in preventing the proliferation of cancer cells.1,2Docetaxel has potential applications in breast cancer and hormone-refractory prostate cancer.3,4

1.Bissery, M.C., Guenard, D., Gueritte-Voegelein, F., et al.Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogueCancer Research514845-4852(1991) 2.Pazdur, R., Kudelka, A.P., Kavanagh, J.J., et al.The taxoids: Paclitaxel (Taxolr) and docetaxel (Taxoterer)Cancer Treatment Reviews19351-386(1993) 3.Mahon, K.L., Henshall, S.M., Sutherland, R.L., et al.Pathways of chemotherapy resistance in castration-resistant prostate cancerEndocrine-Related Cancer18R103-R123(2011) 4.Yao, X., Hosenpud, J., Chitambar, C.R., et al.A phase II study of concurrent docetaxel, epirubicin and cyclophospha-mide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancerJournal of Cancer3145-151(2012)